Obermatt
See Similar Stocks →

NewAmsterdam Pharma Company

NMQ:NAMS · NL00150012L7
BiotechnologySmall

360

16
Profit price70
Owner Earnings Yield1
Dividend Yield1
Price/Sales3
EV / Gross Profit4
Price/Book19
Return on Capital43
Cash Return on Capital39
Return on Equity48
Profit margins41
Accruals26
Owner Earnings Margin18
Sales growth61
Profit growth1
Reinvestment89
Price momentum75
Debt load100
Refinancing21
Debt Payback1
Liquidity28
Analyst ratings46
Opinion Changes20
Price Target Upside53
Market mood86
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

NewAmsterdam Pharma Company doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryNetherlands
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Employees90
Websiteir.newamsterdampharma.com
ISINNL00150012L7
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DiabetesCardiovascularNeurologyChronic DiseasesCentral Nervous SystemBiotechnologyLife SciencePharmaceutical

Description

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company. The company seeks to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (‘LDL-C’) lowering therapy. In multiple Phas…

Analysis

Hope premium

NewAmsterdam Pharma Company N.V. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
49
2026

All-time high

49

Jun 2026

All-time low

44

Mar 2026

Average rank

47

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
3
—
—
—
Price/Earnings
92
—
—
—
Price/Book
19
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
16
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare NewAmsterdam Pharma Company with its peers
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
GH Research
NMQ:GHRS
57
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kiniksa Pharmaceuticals
NSQ:KNSA
99
CountryUK
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Pentixapharm
GER:PTP
22
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Small
Full Stock Analysis →
Pharming
AEX:PHARM
77
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
SHL Telemedicine
SWX:SHLTN
24
CountryIsrael
IndustryHealth Care Providers & Services
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →